<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615923</url>
  </required_header>
  <id_info>
    <org_study_id>2019P003518D</org_study_id>
    <nct_id>NCT04615923</nct_id>
  </id_info>
  <brief_title>HEALEY ALS Platform Trial - Regimen D Pridopidine</brief_title>
  <official_title>HEALEY ALS Platform Trial - Regimen D Pridopidine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merit E. Cudkowicz, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prilenia Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial&#xD;
      evaluating the safety and efficacy of investigational products for the treatment of ALS.&#xD;
&#xD;
      Regimen D will evaluate the safety and efficacy of a single study drug, pridopidine, in&#xD;
      participants with ALS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial&#xD;
      evaluating the safety and efficacy of investigational products for the treatment of ALS. This&#xD;
      trial is designed as a perpetual platform trial. This means that there is a single Master&#xD;
      Protocol dictating the conduct of the trial. The HEALEY ALS Platform Trial Master Protocol is&#xD;
      registered as NCT04297683.&#xD;
&#xD;
      Once a participant enrolls into the Master Protocol and meets all eligibility criteria, the&#xD;
      participant will be eligible to be randomized into any currently enrolling regimen. All&#xD;
      participants will have an equal chance of being randomized to any currently enrolling&#xD;
      regimen.&#xD;
&#xD;
      If a participant is randomized to Regimen D Pridopidine, the participant will complete a&#xD;
      screening visit to assess additional Regimen D eligibility criteria. Once Regimen D&#xD;
      eligibility criteria are confirmed, participants will complete a baseline assessment and be&#xD;
      randomized in a 3:1 ratio to either active pridopidine or matching placebo.&#xD;
&#xD;
      Regimen D will enroll by invitation, as participants may not choose to enroll in Regimen D.&#xD;
      Participants must first enroll into the Master Protocol and be eligible to participate in the&#xD;
      Master Protocol before being able to be randomly assigned to Regimen D.&#xD;
&#xD;
      For a list of enrolling sites, please see the HEALEY ALS Platform Trial Master Protocol under&#xD;
      NCT04297683.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 18, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Progression</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bulbar Function in Participants with Bulbar Dysfunction</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in bulbar function over time in participants with bulbar dysfunction at baseline as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bulbar Function in all Randomized Participants</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in bulbar function over time in all randomized participants as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speech</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in speech over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) speech subdomain. The speech question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 4 and a minimum total score of 0. Patients with higher scores have better speech.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Function</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in respiratory function over time as measured by Slow Vital Capacity (SVC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bulbar Function in Participants with Rapid pre-baseline Progression</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in bulbar function over time in participants with rapid pre-baseline progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Bulbar Dysfunction</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Time from baseline to the first observed bulbar dysfunction as measured by an ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain score of less than 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Strength</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in muscle strength over time as measured isometrically using hand-held dynamometry (HHD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Comparison of rate of occurrence between groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Pridopidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pridopidine is administered orally twice daily for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo is administered orally twice daily for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pridopidine</intervention_name>
    <description>Administration: Oral&#xD;
Dose: 45mg twice daily</description>
    <arm_group_label>Pridopidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Administration: Oral&#xD;
Dose: one capsule twice daily</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No additional inclusion criteria beyond the inclusion criteria specified in the Master&#xD;
             Protocol (NCT NCT04297683).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The following exclusion criteria are in addition to the exclusion criteria specified&#xD;
             in the Master Protocol (NCT NCT04297683).&#xD;
&#xD;
               1. Participants with a confirmed prolonged Fridericia-corrected QT (QTcF) interval&#xD;
                  (defined as a QTcF interval of &gt;450 ms for men and &gt;470 ms for women).&#xD;
&#xD;
               2. Participants with clinically significant heart disease, clinically significant&#xD;
                  history of arrhythmia, symptomatic or uncontrolled atrial fibrillation despite&#xD;
                  treatment, or asymptomatic sustained ventricular tachycardia, or presence of left&#xD;
                  bundle branch block.&#xD;
&#xD;
               3. Participants with known history of long QT syndrome or a first degree relative&#xD;
                  with this condition.&#xD;
&#xD;
               4. Participants using prohibited medications within the 4 weeks prior to the Regimen&#xD;
                  Specific Screening Visit, as detailed in section 5.9.&#xD;
&#xD;
               5. Participants using the following medications at the time of the Regimen Specific&#xD;
                  Screening Visit:&#xD;
&#xD;
                    1. Nuedexta - at a dosage higher than 20 mg dextromethorphan + 10 mg quinidine&#xD;
                       BID&#xD;
&#xD;
                    2. Citalopram - at a dosage higher than 20 mg/day&#xD;
&#xD;
                    3. Escitalopram - at a dosage higher than 10 mg/day&#xD;
&#xD;
               6. Participants with a known allergy to any ingredient of the study intervention&#xD;
                  (pridopidine, silicified microcrystalline cellulose, and magnesium stearate).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merit Cudkowicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Healey Center for ALS at Mass General</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>December 25, 2020</last_update_submitted>
  <last_update_submitted_qc>December 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Merit E. Cudkowicz, MD</investigator_full_name>
    <investigator_title>Chief, Neurology Department</investigator_title>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Placebo-Controlled</keyword>
  <keyword>Double-Blind</keyword>
  <keyword>Regimen Specific Appendix</keyword>
  <keyword>Lou Gehrig's Disease</keyword>
  <keyword>Pridopidine</keyword>
  <keyword>Prilenia Therapeutics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

